triple glp-1/gip/glucagon receptor agonist Retatrutide just had its biggest data year yet. In 2026, Eli Lilly's posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling:

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A

a comprehensive review

Established risk factors include: History of pancreatitis: Patients with prior episodes face substantially higher recurrence risk and require careful consideration before initiating GLP-1 therapy Gallstone disease: Cholelithiasis and biliary sludge can precipitate pancreatitis, particularly during periods of rapid weight loss Hypertriglyceridemia: Triglyceride levels 1,000 mg/dL significantly increase pancreatitis risk, with risk beginning to rise at levels 500 mg/dL Excessive alcohol consumption: Alcohol remains one of the most common pancreatitis triggers and may interact with metabolic changes induced by GLP-1 medications Obesity and rapid weight loss: While weight reduction is therapeutic, very rapid loss may increase gallstone formation Warning signs of acute pancreatitis that patients should recognize include severe, persistent abdominal pain, typically in the upper abdomen and often radiating to the back

If you've been on the sidelines because needles weren't something you were willing to deal with, it's worth having a fresh conversation with your doctor

If youre struggling with Mounjaros $1,069/month price tag, insurance denial, or availability issues, understanding your alternatives helps you access the same effective medication without breaking the bank or going without treatment

Kim, Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea, Endocrinol